Skip to search formSkip to main contentSkip to account menu

pegaptanib Prefilled Syringe [Macugen]

National Institutes of Health

Related topics

Related topics

3 relations

Narrower (1)

0.09 ML pegaptanib 3.33 MG/ML Prefilled Syringe [Macugen]
MacugenPrefilled Syringe

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2013
2013
Indications et traitement de la dégénérescence maculaire liée à l'âge (DMLA) en pratique
Objectif?: decrire et analyser les pratiques diagnostiques et therapeutiques en matiere de degenerescence maculaire liee a l’âge… 
2010
2010
Monotherapie der exsudativen altersbedingten Makuladegeneration bei kardiovaskulären Risikopatienten
ZusammenfassungHintergrundMit der intravitrealen Applikation von Ranibizumab (Lucentis®) oder Pegaptanib (Macugen®) stehen… 
2010
2010
Intravitreal Ranibizumab (Lucentis®) Is More Effective Than Intravitreal Pegaptanib (Macugen®) in Treating Exsudative Age-Related Macular Degeneration for Patients With History of Cardiovascular…
2009
2009
Potential use of biodegradable nanoparticles for the photodynamic therapy of eye diseases.
Nowadays, the most common application of photodynamic therapy (PDT) in ophthalmology is the treatment of specific types of age… 
2007
2007
Pegaptanib Sodium (Macugen®) as an Adjunct in the Management of Refractory Proliferative Diabetic Retinopathy and Clinically Significant Macular Edema
2007
2007
The suppression of early angiogenic markers by the antiangiogenic aptamer Macugen® is dose dependent
The suppression of early angiogenic markers by the antiangiogenic aptamer Macugen R is dose dependent 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)